<DOC>
	<DOCNO>NCT00054418</DOCNO>
	<brief_summary>RATIONALE : Preventing bone loss patient receive chemotherapy breast cancer may decrease risk fracture may help patient live comfortably . It yet know whether calcium effective without risedronate prevent bone loss . PURPOSE : This randomized phase III trial study two form calcium without risedronate compare well work prevent bone loss premenopausal woman receive chemotherapy primary stage I , stage II , stage IIIA , stage IIIB breast cancer .</brief_summary>
	<brief_title>Risedronate Preventing Bone Loss Premenopausal Women Receiving Chemotherapy Primary Breast Cancer</brief_title>
	<detailed_description>OUTLINE : This randomize , placebo-controlled , double-blind study . Patients stratify accord plan tamoxifen therapy ( yes v v undecided ) , plan taxane therapy ( yes v v undecided ) , time last menses ( 1-3 month vs longer 3 month 6 month ) , age ( 40 vs 40 49 v 50 ) . Patients randomize 1 2 treatment arm . In arm , treatment begin first month chemotherapy continue 1 year absence unacceptable toxicity . For information regard treatment arm , please see `` Arms '' section . Questionnaires cessation menses , ovarian failure , menopausal symptom complete baseline , monthly chemotherapy , 6 month , 1 2 year . Patients follow 1 year . A summary study goal list . Goals : 1 . To evaluate effectiveness risedronate weekly oral dose 35 mg versus placebo prevention bone loss premenopausal woman undergo adjuvant neoadjuvant chemotherapy primary breast cancer . 2 . To evaluate degree bone loss one year premenopausal woman undergo adjuvant chemotherapy primary breast cancer accord menopausal status one year therapy begin . 3 . To evaluate relationship current climacteric symptom , menstrual reproductive history , chemotherapy regimen ovarian failure ( permanent cessation menses ) premenopausal woman undergo adjuvant neoadjuvant chemotherapy primary breast cancer . 4 . To evaluate relationship baseline serum estradiol level ovarian failure premenopausal woman undergo adjuvant neoadjuvant chemotherapy primary breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>1 . Required Characteristics 1 . Premenopausal woman ≤ 6 month since last menstrual period prior bilateral oophorectomy estrogen replacement therapy TAH perform , least one intact ovary , &gt; 3 month since last menstrual period , patient must premenopausal estrogen level ≤ 1 month study entry 2 . Scheduled undergo adjuvant neoadjuvant chemotherapy primary breast cancer ( stage IIIIB ) 3 . ≥ 18 year age 4 . ECOG performance status ( PS ) 0 1 2 . Contraindications 1 . Hypercalcemia ( calcium level &gt; 1mg/dL UNL ≤ 6 month 2 . Hypocalcemia ( calcium level &gt; 0.5 mg/dL UNL ≤ 6 month 3 . Inability stand sit upright least 30 minute 4 . Known swallow disorder 5 . Bone mineral density T score ≤ 2.0 hip lumbar spine patient T score 2.1 ineligible patient T score 1.9 eligible 6 . History vertebral compression fracture Exception : traumatic fracture coccyx would exclude patient participation 7 . Corticosteroids dose &gt; 5 mg daily prednison equivalent &gt; 2 week past 6 month 8 . Previous treatment bisphosphonates 9 . Diseases affect bone metabolism ( hyperthyroidism , hyperparathyroidism , hypercortisolism ) 10 . History severe renal impairment creatinine &gt; 2.0 mg/dL 11 . Malabsorption syndrome 12 . Estrogen replacement therapy 13 . Oral contraceptive use 14 . Prior bilateral oophorectomy 15 . Pregnant woman Nursing woman Women childbearing potential unwilling employ adequate contraception ( condom , diaphragm , injection , intrauterine device [ IUD ] , surgical sterilization , abstinence , etc . ) This study involve investigational agent whose genotoxic , mutagenic teratogenic effect develop fetus newborn unknown 16 . Dental extraction , root canal , implant ≤ 3 month prior registration plan study treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>